NasdaqGS:SNDXBiotechs
Syndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses Persist
Syndax Pharmaceuticals stock closed up 4.4% at US$19.92, a sharp move for a company that came into this week with a slightly negative 30 day return and a soft 90 day run. The headline today is simple: Q2 revenue reached US$72.8m with Revuforj and Niktimvo together delivering US$115m in quarterly commercial sales, and management reiterated that the balance sheet is funded to support late stage programs.
Short term traders are reacting to the bounce. Long term investors are likely focused on...